Hexarelin
Also known as: GHRP-6 analog, His-D-2-methylTrp-Ala-Trp-D-Phe-Lys-NH2, Examorelin, EP23905, MF-6003
Synthetic growth hormone-releasing peptide (GHRP); Growth hormone secretagogue (GHS); GHS receptor agonist
What it is
Hexarelin is a peptide people use to stimulate growth hormone release for body composition, recovery, and aging. It also shows potential for cardiovascular protection in animal studies, acting directly on heart tissue. Not FDA-approved; likely WADA-prohibited; most human evidence comes from GH diagnostic studies rather than therapeutic trials.
The scientific side
Hexarelin is a synthetic hexapeptide (His-D-2-methylTrp-Ala-Trp-D-Phe-Lys-NH2), a non-natural superanalog of GHRP-6, that acts as a potent agonist at growth hormone secretagogue receptors (GHS-R1a) present at both the pituitary and hypothalamic levels, as well as in peripheral tissues including heart, adrenal glands, ovary, testis, lung, and skeletal muscle. It stimulates GH release via a mechanism distinct from GHRH, likely involving counteraction of somatostatinergic activity and/or partial GHRH-mediated pathways. Hexarelin also stimulates prolactin and ACTH/cortisol secretion, and its effect on the HPA axis appears to involve stimulation of arginine vasopressin (AVP) release rather than CRH. Beyond neuroendocrine effects, hexarelin exerts GH-independent cardiovascular actions via specific cardiac GHS receptors, anti-apoptotic and cytoprotective effects in cardiomyocytes, and PPARγ-activating effects through CD36. Neuroprotective properties have been demonstrated in several in vitro and animal models.
Class: Synthetic growth hormone-releasing peptide (GHRP); Growth hormone secretagogue (GHS); GHS receptor agonist
At a glance
| What it is | A synthetic 6-amino-acid growth hormone-releasing peptide (GHRP), also called examorelin. |
|---|---|
| FDA status | Not approved for any use. Not named on FDA's compounding safety-risk page. |
| Used for | Strong growth hormone release; studied for growth hormone deficiency and heart function. |
| Human evidence | Small 1990s-2000s studies in healthy adults, children and heart patients. |
| Half-life | Not reported in humans. About 2 hours after IV dosing in dogs. |
| Banned in sport | Yes. WADA names "examorelin (hexarelin)" under S2.2.4, prohibited at all times. |
What is Hexarelin?
Hexarelin (examorelin) is a synthetic hexapeptide, a growth hormone-releasing peptide in the same family as GHRP-6 and Ipamorelin. Early human studies showed it released growth hormone after IV, under-the-skin, nasal and even oral doses.
It is less selective than ipamorelin: each dose also raises the stress hormones ACTH and cortisol, and prolactin.
How does it work?
Hexarelin activates the ghrelin receptor (GHS-R1a), triggering a large growth hormone pulse. In people with growth hormone deficiency caused by a disconnection between the hypothalamus and pituitary, it barely worked, which suggests its effect depends on the hypothalamus.
It also binds CD36, a receptor in heart tissue, which is how researchers explain its direct heart effects in animals.
Pharmacokinetics
| Half-life | Not reported in humans; terminal half-life about 120 minutes after IV dosing in dogs |
|---|---|
| Metabolism | Not characterized in humans |
| Clearance | Not characterized in humans |
| Route | Active by IV, subcutaneous, nasal and oral routes in humans; usually injected under the skin |
Is it FDA-approved?
No. Hexarelin has never been approved anywhere for any use.
FDA's page of compounding substances with significant safety risks does not name hexarelin, and it has not been on a Pharmacy Compounding Advisory Committee agenda. Related GHRPs (GHRP-2, GHRP-6) are on FDA's Category 2 list.
- WADA: S2.2.4 Growth hormone releasing factors (named as "examorelin (hexarelin)" among GHRPs; prohibited at all times)
History
Hexarelin was studied intensively in the 1990s. A 1994 study showed it released growth hormone by four routes of administration, and dose-response studies followed in adults and children.
Researchers tested it in children with short stature and growth hormone deficiency, in older adults, and in heart patients, where it acutely improved heart pumping. It was never developed into an approved drug and is now sold as a research peptide.
Regulatory timeline
Side effects
Each injection briefly raises other pituitary hormones. In healthy adults, 2 micrograms/kg IV roughly doubled ACTH and raised cortisol by about 24%. Prolactin rose by up to about 180% at higher doses.
With repeated use these spikes fade. After 16 weeks of twice-daily injections in older adults, the authors concluded that "over-stimulation of the pituitary adrenal axis and prolactin secretion do not occur." People with pituitary or adrenal conditions should get medical advice before using it.
Common
- Brief rises in ACTH and cortisol after each dose
- Brief rise in prolactin after each dose
Who should not use it
- No established contraindications: hexarelin never completed development.
- Competitive athletes: Prohibited at all times under WADA S2.2.4 (growth hormone releasing factors), per the 2026 World Anti-Doping Code Prohibited List. Verified against the current WADA list as of October 2026.
- Pituitary or adrenal disorders: each dose raises ACTH and cortisol; in Cushing's disease the ACTH rise was about 7 times that of CRH.
- Active cancer: it raises growth hormone, a growth factor.
Small physiology studies in healthy adults (Ghigo 1997, Massoud 1996) and a 16-week study in older adults (Rahim 1998, 1999).
What does the research show?
In a 16-week study of twice-daily injections (1.5 micrograms/kg) in older adults, the growth hormone response to a test dose fell from 19.1 to 10.5 µg/L·h, about 45%, and recovered fully 4 weeks after stopping. IGF-1, body fat, lean mass and bone density did not change.
In adults with growth hormone deficiency and in healthy controls, a single dose acutely raised left ventricular ejection fraction, a measure of heart pumping. Response varies with age, and the GH response is weaker in people with pituitary disease.
Studied for
- Growth hormone deficiency and short stature in children
- Growth hormone release in older adults (16-week study)
- Heart function in adults with GH deficiency and in heart failure (single-dose studies)
FAQ
Does Hexarelin raise cortisol and prolactin?
Yes, briefly after each dose: in healthy adults ACTH roughly doubled and cortisol rose about 24%, and prolactin rose up to about 180%. With 16 weeks of use these rises faded.
Does Hexarelin stop working over time?
Partly. After 16 weeks of twice-daily injections the growth hormone response fell about 45%, and it recovered 4 weeks after stopping.
Sources: [11]
Does Hexarelin raise IGF-1?
Not in the 16-week study: IGF-1 did not change significantly.
Sources: [11]
Does Hexarelin affect the heart?
In single-dose studies it acutely raised heart pumping (ejection fraction). It binds CD36, a receptor in heart tissue.
Is Hexarelin banned in sport?
Yes. The 2026 WADA Prohibited List names "examorelin (hexarelin)" under S2.2.4, prohibited at all times.
Sources: [14]
Citations
- Ghigo E, et al. Growth hormone-releasing activity of hexarelin after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab 1994. PMID 8126144
- Ghigo E, et al. Adrenocorticotropin- and cortisol-releasing effect of hexarelin in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab 1997. PMID 9253314
- Loche S, et al. The effect of hexarelin on growth hormone secretion in patients with GH deficiency. J Clin Endocrinol Metab 1995. PMID 7673411
- Bodart V, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res 2002. PMID 11988484
- Roumi M, et al. Radioimmunoassay for hexarelin and its pharmacokinetic studies. Peptides 1995. PMID 8545255
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee (agenda). fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- Massoud AF, et al. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. J Clin Endocrinol Metab 1996. PMID 8954038
- Bisi G, et al. Cardiac effects of hexarelin in hypopituitary adults. Eur J Pharmacol 1999. PMID 10528131
- Rahim A, et al. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. Clin Endocrinol (Oxf) 1999. PMID 10341859
- Rahim A, et al. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab 1998. PMID 9589671
- Arvat E, et al. The GH, prolactin, ACTH and cortisol responses to hexarelin undergo different age-related variations. Eur J Endocrinol 1997. PMID 9437229
- Maccario M, et al. Impact of two or three daily subcutaneous injections of hexarelin on 24-h GH, prolactin, ACTH and cortisol secretion. Eur J Endocrinol 2002. PMID 11888836
- World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
Sources
- Ghigo 1994. Ghigo E, et al. Growth hormone-releasing activity of hexarelin after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab 1994. pubmed.ncbi.nlm.nih.gov/8126144
- Massoud 1996. Massoud AF, et al. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. J Clin Endocrinol Metab 1996. pubmed.ncbi.nlm.nih.gov/8954038
- Ghigo 1997. Ghigo E, et al. Adrenocorticotropin- and cortisol-releasing effect of hexarelin in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab 1997. pubmed.ncbi.nlm.nih.gov/9253314
- Arvat 1997. Arvat E, et al. The GH, prolactin, ACTH and cortisol responses to hexarelin undergo different age-related variations. Eur J Endocrinol 1997. pubmed.ncbi.nlm.nih.gov/9437229
- Loche 1995. Loche S, et al. The effect of hexarelin on growth hormone secretion in patients with GH deficiency. J Clin Endocrinol Metab 1995. pubmed.ncbi.nlm.nih.gov/7673411
- Roumi 1995. Roumi M, et al. Radioimmunoassay for hexarelin and its pharmacokinetic studies. Peptides 1995. pubmed.ncbi.nlm.nih.gov/8545255
- Rahim 1998. Rahim A, et al. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab 1998. pubmed.ncbi.nlm.nih.gov/9589671
- Rahim 1999. Rahim A, et al. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. Clin Endocrinol (Oxf) 1999. pubmed.ncbi.nlm.nih.gov/10341859
- Bisi 1999. Bisi G, et al. Cardiac effects of hexarelin in hypopituitary adults. Eur J Pharmacol 1999. pubmed.ncbi.nlm.nih.gov/10528131
- Maccario 2002. Maccario M, et al. Impact of two or three daily subcutaneous injections of hexarelin on 24-h GH, prolactin, ACTH and cortisol secretion. Eur J Endocrinol 2002. pubmed.ncbi.nlm.nih.gov/11888836
- Bodart 2002. Bodart V, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res 2002. pubmed.ncbi.nlm.nih.gov/11988484
- FDA. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA (2024 archive). FDA: the same page as archived September 28, 2024. web.archive.org/web/20240928064141/https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA PCAC, July 2026. FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee (agenda). fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- WADA. World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
Administration & storage
- Administration
- Intravenous (i.v.) bolus — used in multiple human clinical studies (PMID: 81261441214494110469018108864889062497928593992310489425393104048258954038)Subcutaneous (s.c.) injection — used in human studies including 16-week twice-daily protocol (PMID: 812614495896711034185910197083)Intranasal administration — evaluated in human volunteers and children (PMID: 81261447955465)Oral administration — evaluated in human volunteers with low bioavailability (0.3%) (PMID: 812614411578108)Intraperitoneal (i.p.) injection — used in mouse studies (PMID: 3487133642619489)
- Storage
- No storage conditions for hexarelin are described in any of the reviewed abstracts.
- Cautions
- Hexarelin stimulates ACTH and cortisol secretion acutely in humans; prolonged or high-dose use could theoretically affect the HPA axis, though one 16-week twice-daily s.c. study found no significant overactivation of the pituitary-adrenal axis.,Hexarelin stimulates prolactin release in humans; concerns about repeated episodes of transient hyperprolactinaemia with long-term therapy have been noted, though not confirmed as clinically significant in a 16-week study.,Partial, reversible desensitization of the GH response has been documented with chronic twice-daily s.c. administration over 16 weeks; this may limit long-term therapeutic utility.,Oral bioavailability is very low (0.3%), and intestinal degradation by proteases is a known pharmacological limitation; permeation enhancers investigated in animal studies did not consistently improve hexarelin absorption.,Hexarelin is listed among unregulated performance-enhancing peptides used via self-administration, with uncertainty around product composition, dose, and purity in unregulated supply chains. Sterile technique is essential for any injectable administration.,No long-term human safety data on cancer incidence, mortality, or other endpoints are available for hexarelin specifically; general GHS safety data are limited.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification. One review notes absence of regulatory approval for physique- or performance-related indications; another notes strict FDA criteria exist for GH use…
Not stated in reviewed literature — requires manual verification. One review classifies hexarelin among performance-enhancing peptides modulating the GH-IGF1 axis, but does not explicitly state WADA prohibition status.
Not stated in reviewed literature — requires manual verification.
What it's studied for
- GH secretagogue / diagnostic test for GH reserve Human observational
- Hexarelin administered i.v., s.c., intranasally, and orally produced dose-dependent GH release in healthy volunteers. Biological bioavailabilities: 77% (s.c.), 4.8% (intranasal), 0.3% (oral). GH response to 1 µg/kg i.v. hexarelin was approximately 2-fold higher than 1 µg/kg GHRH. PMID 8126144 Ghigo E et al. J Clin Endocrinol Metab. 1994
- In 19 patients with possible pituitary disease, subnormal GH response to hexarelin (2 µg/kg i.v.) predicted GH deficiency on insulin tolerance test. Authors suggest hexarelin could serve as a screening test for adult GH deficiency, particularly when ITT is contraindicated. PMID 10469018 Korbonits M et al. Clin Endocrinol. 1999
- 16 weeks of twice-daily s.c. hexarelin (1.5 µg/kg) in elderly subjects caused partial, reversible attenuation of GH response. IGF-I, IGFBP-3, body composition, and bone mineral density did not change significantly; one bone formation marker (C-terminal propeptide of type I collagen) increased. PMID 9589671 Rahim A et al. J Clin Endocrinol Metab. 1998
- In prepubertal short normal children, hexarelin (2 µg/kg i.v.) GH response had limited intraindividual variability (CV ~23%). Testosterone and ethinyl estradiol, but not oxandrolone, augmented the GH response, suggesting estrogen mediation. PMID 9062497 Loche S et al. J Clin Endocrinol Metab. 1997
- Cardiovascular protection / cardiac function improvement Mixed
- Acute hexarelin (2.0 µg/kg i.v.) in patients with coronary artery disease undergoing bypass surgery significantly increased LVEF, cardiac index, and cardiac output within 10 min, lasting up to 90 min. Effects not shared by GHRH or rhGH, indicating GH-independent cardiovascular GHS receptor activation. PMID 12144941 Broglio F et al. Eur J Pharmacol. 2002
- In a murine myocardial ischemia-reperfusion model, hexarelin (0.3 mg/kg/day for 21 days, first dose immediately prior to reperfusion) significantly improved LV function, decreased interstitial collagen and TGF-β1, and reduced cardiac troponin-I and TNF-α levels. PMID 32403043 McDonald H et al. Biomed Pharmacother. 2020
- Hexarelin (200 µg/kg twice per day) in a mouse elastase-induced abdominal aortic aneurysm model decreased aortic diameter, improved elastin preservation, rescued smooth muscle cell contractile phenotype, and inhibited NLRP3 inflammasome and NF-κB signaling. PMID 34856183 Jiang B et al. Microvasc Res. 2022
- Chronic hexarelin injection (s.c. BID, 30 days) in rats with diet/vitamin D3-induced atherosclerosis suppressed plaque formation, partially reversed HDL-c/LDL-c ratio, increased vascular NO and eNOS mRNA, decreased VSMC proliferation, and reduced foam cell formation. PMID 19931584 Pang J et al. Peptides. 2010
- In anesthetized Sprague-Dawley rats, acute hexarelin evoked coronary microvascular dilation via GHS-R1a, nitric oxide, and endothelium-derived hyperpolarization. However, chronic hexarelin prior to sugen chronic hypoxia did not prevent RV hypertrophy or RV cardiomyocyte relaxation impairment in a pulmonary hypertension PMID 35126171 Waddingham MT et al. Front Physiol. 2021
- Neuroprotection (ALS model, oxidative stress, optic nerve injury) Animal studies only
- Hexarelin (1 µM) protected human neuroblastoma SH-SY5Y SOD1-G93A cells from H2O2-induced cytotoxicity by activating molecules regulating apoptosis and promoting cell survival, suggesting potential in ALS therapy. PMID 36674509 Meanti R et al. Int J Mol Sci. 2023
- In golden hamsters following optic nerve transection, single daily doses of hexarelin (25, 50, 100 µg/kg) dose-dependently increased retinal ganglion cell survival. Two daily doses of 150 µg/kg hexarelin were optimal for RGC survival. PMID 41766237 Chow KBS. Indian J Pharmacol. 2026
- Hexarelin inhibited H2O2-induced apoptosis in Neuro-2A cells by improving cell viability, reducing NO release, downregulating caspase-3/7 and Bax mRNA, inhibiting MAPK phosphorylation, and increasing p-Akt expression. PMID 34066741 Meanti R et al. Pharmaceuticals. 2021
- Metabolic disorders / diabetes / atherosclerosis (CD36-PPARγ pathway) Animal studies only
- Review summarizing hexarelin's role as a potent inducer of PPARγ through CD36 activation, with reported benefits on atherosclerosis, hepatic cholesterol biosynthesis, and fat mitochondrial biogenesis in animal models. PMID 29883404 Maréchal L et al. Int J Mol Sci. 2018
- Review: hexarelin has been reported to regulate PPARγ in macrophages and adipocytes and may exert GH-independent cardiovascular and metabolic activities relevant to diabetes and diabetic cardiomyopathy. PMID 25045704 Mosa RMH et al. Endocrine. 2015
- Organ protection (kidney, lung, pancreas) against ischemia/reperfusion and toxic injury Animal studies only
- In I/R-induced AKI rats, hexarelin pretreatment (100 µg/kg/d for 7 days) mitigated tubular necrosis, improved renal function, and inhibited apoptosis via downregulation of Caspase-3, Bax, Bad and upregulation of Bcl-2, potentially through MDM2/p53 pathway. PMID 37710348 Guan C et al. Eur J Med Res. 2023
- In a murine HCl-induced ARDS model, hexarelin (320 µg/kg i.p.) before or after challenge improved lung compliance, reduced immune cell recruitment and neutrophils in BAL, and reduced pulmonary collagen deposition at day 14. PMID 34871336 Zambelli V et al. Drug Target Insights. 2021
- Hexarelin (10 µg/kg i.p.) administered twice (4-h intervals) before or after intranasal MPTP in mice significantly reduced pulmonary histopathological damage, Caspase-3 and IL-6 expression, and improved SOD immunoreactivity. PMID 42619489 Celikoglu O et al. J Basic Clin Physiol Pharmacol. 2026
- Hexarelin attenuated MPTP-associated pancreatic injury in BALB/c mice, reducing inflammatory markers (CD11b, CD68, IL-1β, TNF-α), apoptosis (caspase-3), and β-amyloid immunoreactivity while partially preserving islet morphology and insulin immunoreactivity. PMID 42758352 Şahin M et al. J Mol Histol. 2026
- HPA axis stimulation / diagnostic use in Cushing's disease differentiation Human observational
- Randomized single-blind study: hexarelin (2 µg/kg i.v.) induced striking ACTH/cortisol responses in Cushing's disease patients but not in alcohol-induced pseudo-Cushing's syndrome, suggesting utility in differential diagnosis. PMID 10886488 Coiro V et al. J Intern Med. 2000
- Hexarelin's stimulation of HPA axis in healthy young males appears mediated by AVP, not CRH, based on combination studies with desmopressin and CRH. PMID 10404825 Korbonits M et al. J Clin Endocrinol Metab. 1999
- Sleep modulation Human observational
- In 7 young healthy male volunteers, repetitive hexarelin (4 × 50 µg at 22:00, 23:00, 24:00, 01:00 h) decreased stage 4 slow-wave sleep and EEG delta power, and increased GH, prolactin, ACTH, and cortisol. Leptin and TNF-α were unchanged. Authors hypothesize sleep impairment is due to shift in GHRH/CRH ratio in favour o PMID 15177700 Frieboes RM et al. Psychoneuroendocrinology. 2004
- Attenuation of morphine analgesic tolerance Animal studies only
- In Wistar rats, hexarelin (0.2 mg/kg) combined with morphine attenuated analgesic tolerance to morphine and enhanced antinociception in tail-flick and hot-plate tests. PMID 32893668 Baser T et al. Can J Physiol Pharmacol. 2021
- Growth velocity improvement in short stature / GH deficiency Human observational
- Review noting that in short children, an increase in height velocity has been reported during chronic GHRP treatment; GHRPs including hexarelin have shown clinical usefulness for stimulating GH secretion in some GH hyposecretory states. PMID 9186261 Ghigo E et al. Eur J Endocrinol. 1997
- Review noting potential role of GHRPs in treatment of short stature, aging, catabolic states, and dilated cardiomyopathy. PMID 9465289 Camanni F et al. Front Neuroendocrinol. 1998
Protocol
100 mcg subcutaneous injection, 2-3x per day. Cycle: 4-8 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Intravenous, subcutaneous, intranasal, oral | 1 µg/kg and 2 µg/kg i.v.; 1.5 µg/kg and 3 µg/kg s.c.; 20 µg/kg intranasal; 20 mg and 40 mg oral | Single administration | human | Research PMID 8126144 |
| Subcutaneous | 1.5 µg/kg twice daily s.c. | 16 weeks | human | Research PMID 9589671 |
| Subcutaneous | 1.5 µg/kg twice daily s.c. | 16 weeks | human | Research PMID 10341859 |
| Intravenous | 2.0 µg/kg i.v. (single acute dose) | Single administration | human | Research PMID 12144941 |
| Intravenous | 2 µg/kg i.v. | Single administration | human | Research PMID 10469018 |
| Intravenous | 2 µg/kg i.v. | Single administration | human | Research PMID 10886488 |
| Intravenous | 0–1.0 µg/kg i.v. (dose-response; 0, 0.125, 0.25, 0.5, 1.0 µg/kg) | Single administration | human | Research PMID 8954038 |
| Not specified (context implies i.v. or s.c.) | 4 × 50 µg (given at 22:00, 23:00, 24:00, and 01:00 h) | Single night | human | Research PMID 15177700 |
| Intravenous | 2 µg/kg i.v. | Single administration | human | Research PMID 9062497 |
| Intravenous | 2 µg/kg i.v. | Single administration | human | Research PMID 9814463 |
| Intravenous | 1 µg/kg i.v. | Single administration | human | Research PMID 9231048 |
| Intravenous | 1 µg/kg and 2 µg/kg i.v. | Single administration | human | Research PMID 9285939 |
| Subcutaneous | 1.5 µg/kg s.c. | Single administration | human | Research PMID 10197083 |
| Intravenous; intranasal | 1 µg/kg i.v. and 20 µg/kg intranasal | Single administration | human | Research PMID 7955465 |
| Subcutaneous | Chronic hexarelin injection s.c. BID for 30 days (exact dose per injection not stated in abstract) | 30 days | animal | Research PMID 19931584 |
| Not specified in abstract | 100 µg/kg/day for 7 days before sacrifice | 7 days pretreatment | animal | Research PMID 37710348 |
| Intraperitoneal | 320 µg/kg i.p. | Single administration (before or after HCl challenge) | animal | Research PMID 34871336 |
| Not specified in abstract | 200 µg/kg twice per day | Not specified beyond study period | animal | Research PMID 34856183 |
| Not specified in abstract | 0.3 mg/kg/day for 21 days | 21 days | animal | Research PMID 32403043 |
| Intraperitoneal | 10 µg/kg i.p. twice (4-h intervals) | Single day (two doses 4 h apart) | animal | Research PMID 42619489 |
| Not specified in abstract (injection) | 25 µg/kg, 50 µg/kg, and 100 µg/kg once daily; 100 µg/kg and 150 µg/kg twice daily for 5 days | 5 days | animal | Research PMID 41766237 |
| Not specified in abstract | 0.2 mg/kg | Not specified beyond tolerance induction period | animal | Research PMID 32893668 |
| In vitro | 1 µM | 24 hours incubation | in_vitro | Research PMID 36674509 |
| In vitro | Various concentrations (specific µM values not detailed in abstract excerpt) | 24 hours | in_vitro | Research PMID 34066741 |
| In vitro | Significant responses at 3 µM; maximal effects at ~30 µM | 12–18 hours incubation | in_vitro | Research PMID 12379504 |
| subcutaneous injection | 100 mcg | 2-3x per day · 4-8 weeks | Bodybuilders and biohackers seeking GH pulse stimulation and muscle gain | [Community] |
| subcutaneous injection | 200 mcg | 2x per day · 4-6 weeks | Experienced biohackers and bodybuilders seeking stronger GH pulse | [Community] |
| subcutaneous injection | 200 mcg | 3x per day · 4 weeks | Advanced bodybuilders running aggressive GH-stimulating protocols | [Community] |
| subcutaneous injection | 100 mcg | 1x per day (pre-workout) · 8-12 weeks | Biohackers and fitness-focused users preferring lower-frequency, longer-cycle approach | [Community] |
| subcutaneous injection | 100 mcg | 2x per day · 4-6 weeks on, 4-6 weeks off (cyclical) | Biohackers concerned about Hexarelin receptor desensitization | [Community] |
| subcutaneous injection | 200 mcg | 2x per day · 4-6 weeks on, 4 weeks off | Intermediate to advanced users running Hexarelin in combination with a GHRH (e.g., CJC-1295 or Mod GRF 1-29) | [Community] |
| subcutaneous injection | 100 mcg | 1x per day (before bed) · 8-12 weeks | Anti-aging biohackers and longevity-focused users seeking overnight GH pulse | [Community] |
| subcutaneous injection | 50 mcg | 2x per day · 8-12 weeks | Beginners or users sensitive to GHRP side effects (increased appetite, cortisol, prolactin) | [Community] |
| subcutaneous injection | 200 mcg | 2x per day · 4 weeks on, 4 weeks off | Users seeking cardioprotective or cardiac recovery benefits reported in research literature | [Community] |
| subcutaneous injection | 100 mcg | 2x per day · 4-6 weeks | Post-cycle therapy (PCT) or post-steroid-cycle users seeking endogenous GH axis restoration | [Community] |
All studies (39)
- PMID 8126144 Human observational
GH secretagogue / diagnostic test for GH reserve - PMID 9062497 Human observational
GH secretagogue / diagnostic test for GH reserve - PMID 9186261 Human observational
Growth velocity improvement in short stature / GH deficiency - PMID 9465289 Human observational
Growth velocity improvement in short stature / GH deficiency - PMID 9589671 Human observational
GH secretagogue / diagnostic test for GH reserve - PMID 10404825 Human observational
HPA axis stimulation / diagnostic use in Cushing's disease differentiation - PMID 10469018 Human observational
GH secretagogue / diagnostic test for GH reserve - PMID 10886488 Human observational
HPA axis stimulation / diagnostic use in Cushing's disease differentiation - PMID 15177700 Human observational
Sleep modulation - PMID 12144941 Mixed
Cardiovascular protection / cardiac function improvement - PMID 19931584 Mixed
Cardiovascular protection / cardiac function improvement - PMID 32403043 Mixed
Cardiovascular protection / cardiac function improvement - PMID 34856183 Mixed
Cardiovascular protection / cardiac function improvement - PMID 35126171 Mixed
Cardiovascular protection / cardiac function improvement - PMID 7955465
1 µg/kg i.v. and 20 µg/kg intranasal Intravenous; intranasal (human) - PMID 8954038
0–1.0 µg/kg i.v. (dose-response; 0, 0.125, 0.25, 0.5, 1.0 µg/kg) Intravenous (human) - PMID 9231048
1 µg/kg i.v. Intravenous (human) - PMID 9285939
1 µg/kg and 2 µg/kg i.v. Intravenous (human) - PMID 9814463
2 µg/kg i.v. Intravenous (human) - PMID 10197083
1.5 µg/kg s.c. Subcutaneous (human) - PMID 10341859
1.5 µg/kg twice daily s.c. Subcutaneous (human) - PMID 10790589
- PMID 11578108
- PMID 12379504
Significant responses at 3 µM; maximal effects at ~30 µM In vitro (in_vitro) - PMID 25045704 Animal studies only
Metabolic disorders / diabetes / atherosclerosis (CD36-PPARγ pathway) - PMID 28400207
- PMID 29883404 Animal studies only
Metabolic disorders / diabetes / atherosclerosis (CD36-PPARγ pathway) - PMID 31526442
- PMID 31991924
- PMID 32893668 Animal studies only
Attenuation of morphine analgesic tolerance - PMID 34066741 Animal studies only
Neuroprotection (ALS model, oxidative stress, optic nerve injury) - PMID 34221875
- PMID 34871336 Animal studies only
Organ protection (kidney, lung, pancreas) against ischemia/reperfusion and toxic injury - PMID 36674509 Animal studies only
Neuroprotection (ALS model, oxidative stress, optic nerve injury) - PMID 37710348 Animal studies only
Organ protection (kidney, lung, pancreas) against ischemia/reperfusion and toxic injury - PMID 41766237 Animal studies only
Neuroprotection (ALS model, oxidative stress, optic nerve injury) - PMID 42395176
- PMID 42619489 Animal studies only
Organ protection (kidney, lung, pancreas) against ischemia/reperfusion and toxic injury - PMID 42758352 Animal studies only
Organ protection (kidney, lung, pancreas) against ischemia/reperfusion and toxic injury